Clinical Trial Update: PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 inhibitor alone or in combination with GVD for relapsed/refractory classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• GVD
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN